H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on iTeos Therapeutics (ITOS – Research Report) today and set a price target of $54.00. The company’s shares closed yesterday at $14.58.
Ramakanth covers the Healthcare sector, focusing on stocks such as Ocugen, Electrocore, and Bicycle Therapeutics. According to TipRanks, Ramakanth has an average return of -15.4% and a 29.08% success rate on recommended stocks.
Currently, the analyst consensus on iTeos Therapeutics is a Strong Buy with an average price target of $39.67.
See today’s best-performing stocks on TipRanks >>
Based on iTeos Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $53.91 million and a net profit of $20.45 million. In comparison, last year the company earned a revenue of $240.5 million and had a net profit of $184.87 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Read More on ITOS:
- iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
- Down More Than 50%: 2 ‘Strong Buy’ Stocks That Are Too Cheap to Ignore
- iTeos Therapeutics price target lowered to $33 from $45 at Wedbush
- iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
- iTeos Therapeutics expects cash to provide runway into 2026
